Immunomedics debuts LeukoScan in Europe

Article

Immunomedics of Morris Plains, NJ, last month began shipments to Germany and Austria of LeukoScan, its radiolabeled monoclonal antibody fragment for the detection of infectious disease.Launches in the U.K. and Ireland are expected by the end of May, with

Immunomedics of Morris Plains, NJ, last month began shipments to Germany and Austria of LeukoScan, its radiolabeled monoclonal antibody fragment for the detection of infectious disease.

Launches in the U.K. and Ireland are expected by the end of May, with deliveries to the rest of the European Union countries to follow by the end of August, according to Philippe Barzin, general manager of the company's European subsidiary in Petten, the Netherlands. Barzin will coordinate sales and marketing for LeukoScan in Europe.

Distribution within the European Union will initially be handled by Mallinckrodt's European affiliate, which also partners with Immunomedics to sell and distribute the company's CEA-Scan colorectal cancer imaging agent.

LeukoScan received final clearance from the European Commission in February for sales and marketing in the 15 E.U. nations. The agent is designed for the detection and diagnosis of osteomyelitis involving long bones, particularly in diabetic patients with foot ulcers, according to the company. Immunomedics filed a biologics license application (BLA) for the product with the Food and Drug Administration in December 1996.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.